After the close of trading on the 22nd, Ribomic obtained consent for participation from more than the target enrollment of 16 participants in the domestic Phase III WAKABA trial for children with achondroplasia. Attention is focused on the trial's future progress.
The domestic Phase III clinical trial, known as the WAKABA trial, is underway using the achondroplasia treatment umedaptanib pegol in children aged 2 to 14.
The target enrollment for the trial is 16 people, and the parties involved announced that consent for participation in the clinical trial had been obtained.
Through this development, Ribomic is informing the market of the trial's progress and the status of consent to participate.